General Information of Drug (ID: DM94XJ2)

Drug Name
(1H-indol-2-yl)(5-phenoxy-1H-indol-2-yl)methanone Drug Info
Synonyms CHEMBL210425; (1H-indol-2-yl)(5-phenoxy-1H-indol-2-yl)methanone
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
44411967
TTD Drug ID
DM94XJ2

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Romiplostim DM3U7SZ Thrombocytopenia 3B64 Approved [2]
Ripretinib DM958QB Gastrointestinal stromal tumour 2B5B Approved [3]
Olaratumab DMNYOIX Soft tissue sarcoma 2B57 Approved [4]
Avapritinib DMK2GZX Gastrointestinal stromal tumour 2B5B Approved [5]
E-3810 DM42PFT Solid tumour/cancer 2A00-2F9Z Phase 3 [6]
CP-868596 DMZIM37 Gastrointestinal cancer 2C11 Phase 3 [7]
Famitinib DMSFWT7 Solid tumour/cancer 2A00-2F9Z Phase 2 [8]
XL-820 DMMHX9K Solid tumour/cancer 2A00-2F9Z Phase 2 [9]
MP470 DMELUAK Solid tumour/cancer 2A00-2F9Z Phase 2 [10]
MEDI-575 DMI9WVM Glioblastoma multiforme 2A00.0 Phase 2 [11]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [12]
Romiplostim DM3U7SZ Thrombocytopenia 3B64 Approved [2]
Becaplermin DM1R5X4 Diabetic complication 5A2Y Approved [13]
E-3810 DM42PFT Solid tumour/cancer 2A00-2F9Z Phase 3 [6]
Famitinib DMSFWT7 Solid tumour/cancer 2A00-2F9Z Phase 2 [8]
XL-820 DMMHX9K Solid tumour/cancer 2A00-2F9Z Phase 2 [9]
MK-2461 DM21WBH Alzheimer disease 8A20 Phase 1/2 [14]
SNN-0031 DM2X3BR Brain injury NA07.Z Phase 1/2 [15]
TAK-593 DMNFZOT Solid tumour/cancer 2A00-2F9Z Phase 1 [16]
Pyridine derivative 18 DMBZMYT N. A. N. A. Patented [17]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [18]
Ponatinib DMYGJQO Acute lymphoblastic leukaemia 2A85 Approved [19]
Intedanib DMSTA36 Colorectal cancer 2B91.Z Approved [20]
Midostaurin DMI6E0R Acute myeloid leukaemia 2A60 Approved [21]
Gilteritinib DMTI0ZO Acute myeloid leukaemia 2A60 Approved [22]
Pexidartinib DMS2J0Z Tenosynovial giant cell tumour 2F7B Approved [23]
Pacritinib DM1T6ZN Myelofibrosis 2A20.2 Approved [18]
Quizartinib DM8Y4JS Acute myeloid leukaemia 2A60 Approved [24]
Lestaurtinib DMQ2AIJ Acute myeloid leukaemia 2A60 Approved (orphan drug) [25]
Famitinib DMSFWT7 Solid tumour/cancer 2A00-2F9Z Phase 2 [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fms-like tyrosine kinase 3 (FLT-3) TTGJCWZ FLT3_HUMAN Inhibitor [1]
Platelet-derived growth factor receptor alpha (PDGFRA) TT8FYO9 PGFRA_HUMAN Inhibitor [1]
Platelet-derived growth factor receptor beta (PDGFRB) TTI7421 PGFRB_HUMAN Inhibitor [1]

References

1 Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15.
2 Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
4 A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRalpha) monoclonal antibody, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Mar;73(3):595-604.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
6 E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405.
7 The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations.Invest New Drugs.2015 Apr;33(2):300-9.
8 Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
9 National Cancer Institute Drug Dictionary (drug id 452042).
10 Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Jul;74(1):195-204.
11 Clinical pipeline report, company report or official report of MedImmune (2011).
12 Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
13 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
14 MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
15 Company report (Neuronova)
16 Biochemical characterization of TAK-593, a novel VEGFR/PDGFR inhibitor with a two-step slow binding mechanism. Biochemistry. 2011 Feb 8;50(5):738-51.
17 RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
18 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1807).
19 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
20 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
21 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
22 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
23 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
24 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
25 Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with ... Blood. 2008 Jun 15;111(12):5663-71.